Verition Fund Management’s Syndax Pharmaceuticals SNDX Stock Holding History
Bought
Maintained
Sold
Other funds holding SNDX
KCM
VCM
DM
EP
KCM
HRCM
Verition Fund Management's SNDX Position: Q1 2026 in Review
Verition Fund Management sold out of Syndax Pharmaceuticals (SNDX) in Q1 2026, closing a stake of 18,460 shares — an estimated $388K sold.
Verition Fund Management first reported a position in SNDX in Q4 2020 and held it in 11 quarters. The position peaked at $8.26M in Q1 2024. 246 funds tracked by Wall St. Rank hold SNDX as of Q1 2026.
- Verition Fund Management reported no remaining Syndax Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- Verition Fund Management sold 18,460 Syndax Pharmaceuticals shares in Q1 2026, an estimated $388K.
- Verition Fund Management first reported a position in Syndax Pharmaceuticals in Q4 2020 and held it in 11 quarters.
- Verition Fund Management's Syndax Pharmaceuticals position peaked at $8.26M in Q1 2024.
- 246 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2026.
Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.